Pre-made Lacutamab benchmark antibody ( Whole mAb, anti-KIR3DL2/CD158k therapeutic antibody, Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-290

Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lacutamab is a humanised version of anti KIR3DL2 monoclonal antibody clone #1, and has been shown to have potent activity against KIR3DL2-positive tumours.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-290-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody
INN Name Lacutamab
TargetCD158k
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesUniversity of Genoa;Innate Pharma
Conditions Approvedna
Conditions ActiveMycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome
Conditions Discontinuedna
Development Techna